Genolution

Genolution EBITDA Growth YoY

The Year-over-Year EBITDA Growth of Genolution (225220.KQ) as of Oct 22, 2026 is -7.73 %. In the previous year, Year-over-Year EBITDA Growth was -13.45 % — a change of -42.51% (higher).

EBITDA Growth YoY

-7.73 %

YoY

-42.51%

Last updated:

Year-over-Year EBITDA Growth of Genolution is 2025 -7.73 % . Year-over-Year EBITDA Growth of Genolution was 2024 -13.45 % . It decreases by -42.51% higher compared to the previous year.

The Genolution EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2018
-45.69 KRW
Jan 1, 2019
0.35 KRW
Jan 1, 2020
13,339.03 KRW
Jan 1, 2021
-18.47 KRW
Jan 1, 2022
-64.20 KRW
Jan 1, 2023
-144.50 KRW
Jan 1, 2024
-13.45 KRW
Jan 1, 2025
-7.73 KRW
The Genolution EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
-7.73 %-42.51%
-13.45 %-90.69%
-144.50 %+125.09%
-64.20 %+247.59%
-18.47 %-100.14%
13,339.03 %+3.85 M%
0.35 %-100.76%
-45.69 %-111.94%
382.74 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Year-over-Year EBITDA Growth of Genolution is -7.73 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Genolution since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Genolution historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Growth — Genolution

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — Genolution